336 - Microbiological Outcomes of Oral Omadacycline Treatment in Adults with Nontuberculous Mycobacterial Pulmonary Disease (NTM-PD) Caused by Mycobacterium abscessus complex (MABc): Results from a Phase 2, Double-blind, Randomized, Placebo-controlled, Multi-center Trial

Presenting Author(s)

• RK

  Reeti Khare, PhD

  Director
  National Jewish Health
  Denver, CO, United States

Co-Author(s)

• 

  Diane M. Anastasiou, BS (she/her/hers)

  Director, Microbiology
  Paratek Pharmaceuticals, Inc.
  King of Prussia, PA, United States
• SC

  Surya Chitra, PhD

  Biostatistician
  Paratek Pharmaceuticals, Inc.
  King of Prussia, PA, United States
• 

  Alisa W. Serio, PhD

  Senior Director
  Paratek Pharmaceuticals, Inc.
  King of Prussia, Pennsylvania, United States